Home / Intelligence / Case Studies / Cross-Functional Launch Strategy Alignment Workshop
Trinity organized a full day on-site workshop to bring together key cross functional client teams to align on a final launch strategy for their mNSCLC asset in Japan.
Geographic Scope: 
Client Situation:
The client wanted to build alignment on the launch pricing & market access assumptions for their asset in metastatic non-small cell lung cancer (mNSCLC) and metastatic colorectal cancer (mCRC) in Japan, including consideration of all forecasting assumptions and pricing and market access (P&MA) risks.
Trinity’s Solution:
Trinity conducted targeted secondary research to determine the existing mNSCLC and mCRC treatment paradigm, as well as oncology regulatory landscape in Japan.
Trinity then organized a full-day day workshop at the client’s local office in Japan to enable cross functional client teams to collaborate on forecasting assumptions and optimal launch strategies.
Deliverables
- Case studies of oncology analogues and recent pricing outcomes in JPN
- In-depth policy review of JPN’s new health technology assessment (HTA) process
- Final report with detailed summary of workshop outputs
- Final launch pricing and commercial strategy
Project Outcomes & Impact:
The workshop generated the opportunity for the client’s local team to deliver nuanced local expertise and strategic insights to the global team to ensure that the updated launch forecast model included realistic access assumptions.
Related Intelligence
Blog
Rise with the Waves: UK – Now and Beyond – Four Policy Trends That May Shape Pharma’s Future
Executive Summary The global payer landscape is rapidly evolving and is expected to continuously impact manufacturers’ decisions about new launches, portfolio management, trial design and importantly, pricing and market access strategy. In the UK, several policy reforms have been introduced which are expected to improve patient access while balancing financial healthcare sustainability and overall market […]
Read More
Blog
Japan Pricing Policy Reform 2024
Executive Summary The Central Social Insurance Medical Council, the key Japanese reimbursement policy panel known as Chuikyo, introduced the 2024 drug pricing reform in April 2024. Some key features of the reform plan include: The reform outlines a suite of measures aimed at driving innovation while also addressing drug lags (delay in manufacturers launching drugs in Japan […]
Read More
Webinars
HTA Vision—Implications Beyond the Rating
Available On Demand
A number of critical manufacturer activities are informed by understanding health technology assessment (HTA) agency behavior across geographies and therapeutic areas—from pipeline, business development and licensing to launch planning preparation through to lifecycle management strategy. Join Max Hunt, a Partner in Trinity Life Sciences’ Evidence, Value, Access & Pricing Practice, as he hosts a lively […]
Watch Now